2 results
Approved WMOCompleted
Primary:* To determine if alisertib improves overall response rate (ORR; complete response [CR] plus partial response [PR]) versus a selection of single agents in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL)* To determine…
Approved WMORecruiting
To assess the effect of adding a tapering decision aid on a dynamic flare prediction model to disease-activity-guided dose optimisation (DGDO) on the incidence of flares and medication use.